Free Newsletter
U.K. ratchets up antidepressant warnings
Following the FDA's lead, U.K. regulators have upgraded warnings on all antidepressants to include an increased risk of suicidal thoughts and behavior among young adults taking the meds.
The Medicines and Healthcare Regulatory Agency checked out the FDA's review of safety data, and then concluded that the risk of suicidality was higher in young people. And, the agency said, the risk was the same "across the different antidepressant classes," so labels will be revised not only on SSRIs like Paxil and Prozac, but on other antidepressants such as Effexor and Wellbutrin.
- check out the MHRA's release
- read the item at Pharmalot
Related Article:
Antidepressants - Top 10 Warnings and Recalls of 2007. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: